688298 东方生物
已收盘 11-03 15:00:00
资讯
新帖
简况
股市必读：东方生物新发布《关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-30
股市必读：东方生物新发布《关于召开2026年第三季度业绩说明会的公告》
东方生物(688298.SH)发布前三季度业绩，归母净亏损2.97亿元
智通财经 · 10-28
东方生物(688298.SH)发布前三季度业绩，归母净亏损2.97亿元
图解东方生物三季报：第三季度单季净利润同比下降51.55%
证券之星 · 10-28
图解东方生物三季报：第三季度单季净利润同比下降51.55%
东方生物（688298）10月13日主力资金净卖出207.24万元
证券之星 · 10-14
东方生物（688298）10月13日主力资金净卖出207.24万元
东方基因生物（688298）9月23日主力资金净卖出163.77万元
证券之星 · 09-24
东方基因生物（688298）9月23日主力资金净卖出163.77万元
东方生物：公司目前已取得梅毒螺旋体抗体检测试剂的NMPA证书以及欧盟认证
证券之星 · 09-11
东方生物：公司目前已取得梅毒螺旋体抗体检测试剂的NMPA证书以及欧盟认证
东方生物最新公告：获得多项国际医疗器械注册证
证券之星 · 09-11
东方生物最新公告：获得多项国际医疗器械注册证
东方生物连亏三年半 2020上市募6.38亿光大证券保荐
中金财经 · 09-02
东方生物连亏三年半 2020上市募6.38亿光大证券保荐
东方生物（688298）披露2026年半年度业绩说明会安排，8月31日股价下跌2.74%
证券之星 · 08-31
东方生物（688298）披露2026年半年度业绩说明会安排，8月31日股价下跌2.74%
每周股票复盘：东方生物（688298）股东户数下降6.35%，中报净利亏损2.22亿
证券之星 · 08-30
每周股票复盘：东方生物（688298）股东户数下降6.35%，中报净利亏损2.22亿
东方生物（688298）2026年中报简析：增收不增利，三费占比上升明显
证券之星 · 08-30
东方生物（688298）2026年中报简析：增收不增利，三费占比上升明显
东方生物(688298.SH)发布半年度业绩，归母净亏损2.22亿元
智通财经 · 08-28
东方生物(688298.SH)发布半年度业绩，归母净亏损2.22亿元
图解东方生物中报：第二季度单季净利润同比下降169.46%
证券之星 · 08-28
图解东方生物中报：第二季度单季净利润同比下降169.46%
东方生物(688298)6月30日股东户数1.2万户，较上期减少6.35%
证券之星 · 08-28
东方生物(688298)6月30日股东户数1.2万户，较上期减少6.35%
股市必读：东方生物（688298）6月30日董秘有最新回复
证券之星 · 07-01
股市必读：东方生物（688298）6月30日董秘有最新回复
东方生物：公司2025年度暨2026年第一季度业绩说明会已于2026年5月13日召开
证券之星 · 06-30
东方生物：公司2025年度暨2026年第一季度业绩说明会已于2026年5月13日召开
东方生物：公司已根据实际情况，开展降本增效措施
证券之星 · 06-30
东方生物：公司已根据实际情况，开展降本增效措施
每周股票复盘：东方生物（688298）获多项国际医疗器械认证
证券之星 · 06-28
每周股票复盘：东方生物（688298）获多项国际医疗器械认证
东方生物（688298）披露获得多项医疗器械注册证及认证，6月26日股价下跌4.27%
证券之星 · 06-26
东方生物（688298）披露获得多项医疗器械注册证及认证，6月26日股价下跌4.27%
东方生物跌4.27%创新低 2020年上市募6亿光大证券保荐
中金财经 · 06-26
东方生物跌4.27%创新低 2020年上市募6亿光大证券保荐
加载更多
公司概况
公司名称：
浙江东方基因生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-05
主营业务：
浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是体外诊断试剂、配套仪器。
发行价格：
21.25
{"stockData":{"symbol":"688298","market":"SH","secType":"STK","nameCN":"东方生物","latestPrice":17.24,"timestamp":1793689200000,"preClose":17.29,"halted":0,"volume":1175618,"delay":0,"changeRate":-0.0029,"floatShares":202000000,"shares":202000000,"eps":-3.2653,"marketStatus":"已收盘","change":-0.05,"latestTime":"11-03 15:00:00","open":17.25,"high":17.41,"low":16.96,"amount":20216500,"amplitude":0.026,"askPrice":17.24,"askSize":30,"bidPrice":17.19,"bidSize":22,"shortable":0,"etf":0,"ttmEps":-3.2653,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793755800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.29,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793669400000,1793676600000],[1793682000000,1793689200000]],"highLimit":19.02,"lowLimit":15.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201600000,"isCdr":false,"pbRate":0.61,"roa":"--","roe":"--","epsLYR":-2.98,"committee":-0.06422,"marketValue":3476000000,"turnoverRate":0.0058,"status":1,"afterMarket":{"amount":0,"volume":0,"close":17.24,"buyVolume":0,"sellVolume":0,"time":1793691237746,"indexStatus":"已收盘 11-03 15:30:00","preClose":17.29},"floatMarketCap":3476000000},"requestUrl":"/m/hq/s/688298","defaultTab":"news","newsList":[{"id":"2679256918","title":"股市必读：东方生物新发布《关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2679256918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679256918?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:38","pubTimestamp":1793320711,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘，东方生物报收于17.58元，下跌4.2%，换手率0.76%，成交量1.54万手，成交额2716.74万元。公司公告汇总关于召开2026年第三季度业绩说明会的公告浙江东方基因生物制品股份有限公司将于2026年11月18日10:00–11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司2026年第三季度经营成果、财务状况，并回答投资者提问。投资者可于2026年11月11日至11月17日16:00前通过上证路演中心或公司邮箱zqb@orientgene.com提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000015477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678465363","title":"东方生物(688298.SH)发布前三季度业绩，归母净亏损2.97亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678465363","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678465363?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:34","pubTimestamp":1793183663,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东方生物(688298.SH)披露2026年第三季度报告，前三季度公司实现营收7.18亿元，同比增长6.81%;归属于上市公司股东的净利润亏损2.97亿元;扣非净利润亏损3.15亿元;基本每股收益-1.55元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678345054","title":"图解东方生物三季报：第三季度单季净利润同比下降51.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678345054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678345054?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:56","pubTimestamp":1793181404,"startTime":"0","endTime":"0","summary":"证券之星消息，东方生物2026年三季报显示，前三季度公司主营收入7.18亿元，同比上升6.8%；归母净利润-2.97亿元，同比下降39.82%；扣非净利润-3.15亿元，同比下降35.78%；其中2026年第三季度，公司单季度主营收入2.53亿元，同比下降5.72%；单季度归母净利润-7506.94万元，同比下降51.55%；单季度扣非净利润-7699.1万元，同比下降61.02%；负债率15.27%，投资收益970.76万元，财务费用4519.33万元，毛利率43.57%。财报数据概要请见下图:本文数据来源于东方生物2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800038934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396649","title":"东方生物（688298）10月13日主力资金净卖出207.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396649","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396649?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:33","pubTimestamp":1791937997,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，东方生物报收于18.85元，下跌1.77%，换手率1.01%，成交量2.03万手，成交额3812.38万元。10月13日的资金流向数据方面，主力资金净流出207.24万元，占总成交额5.44%，游资资金净流入117.7万元，占总成交额3.09%，散户资金净流入89.54万元，占总成交额2.35%。融券方面，融券卖出0.0股，融券偿还200.0股，融券余量1.4万股，融券余额26.45万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437374","title":"东方基因生物（688298）9月23日主力资金净卖出163.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437374","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669437374?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:24","pubTimestamp":1790209458,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，东方基因生物报收于19.38元，上涨2.05%，换手率1.05%，成交量2.12万手，成交额4092.44万元。9月23日的资金流向数据方面，主力资金净流出163.77万元，占总成交额4.0%，游资资金净流出263.33万元，占总成交额6.43%，散户资金净流入427.11万元，占总成交额10.44%。融券方面，融券卖出6000.0股，融券偿还2200.0股，融券余量1.05万股，融券余额20.41万元。东方基因生物主营业务：主要从事体外诊断产品的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666652560","title":"东方生物：公司目前已取得梅毒螺旋体抗体检测试剂的NMPA证书以及欧盟认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2666652560","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666652560?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:15","pubTimestamp":1789121742,"startTime":"0","endTime":"0","summary":"证券之星消息，东方生物(688298)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：2026年9月新获梅毒螺旋体抗体检测试剂（胶体金法），有向日本出口的计划吗？东方生物回复：尊敬的投资者您好，公司目前已取得梅毒螺旋体抗体检测试剂的NMPA证书以及欧盟认证，其他国家或地区的证书尚在申报中，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100040195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FSXEmain","688298","BK0239","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544525","title":"东方生物最新公告：获得多项国际医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544525?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:11","pubTimestamp":1789121463,"startTime":"0","endTime":"0","summary":"东方生物(688298.SH)公告称，公司近日取得全自动生化分析仪、荧光免疫分析仪、多通道荧光免疫分析仪及β-hCG、D二聚体、NT-proBNP、心肌肌钙蛋白I、糖化血红蛋白、25-羟基维生素D、C反应蛋白、前列腺特异性抗原、促甲状腺激素等检测试剂盒的医疗器械注册证书，适用地区包括欧盟、瑞士和英国。上述产品取证丰富并完善了公司在欧洲荧光免疫检测、生化检测领域的市场布局，但实际销售业绩取决于产品竞争力和市场能力，对业绩影响尚无法预测。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100039614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1100","BK1574","BK1583","09996","BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664893481","title":"东方生物连亏三年半 2020上市募6.38亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893481","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664893481?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:34","pubTimestamp":1788320051,"startTime":"0","endTime":"0","summary":"中国经济网北京9月2日讯 东方生物 近日披露2026年半年度报告。2026年上半年，公司实现营业收入4.64亿元，同比增长15.15%；归属于上市公司股东的净利润为-2.22亿元，上年同期为-1.63亿元；归属于上市公司股东的扣非净利润为-2.38亿元，上年同期为-1.84亿元；经营活动产生的现金流量净额为-4316.61万元，上年同期为-1.23亿元。 东方生物本次发行费用总额为8,668.22万元，其中承销及保荐费用6,060.16万元。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/02/20260902711483.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/02/20260902711483.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260902/32357485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1147","BK0188","601788","BK0012","06178","IPOS","BK0028","BK0276","688298","BK0183","BK1564","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663771290","title":"东方生物（688298）披露2026年半年度业绩说明会安排，8月31日股价下跌2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663771290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663771290?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:08","pubTimestamp":1788174536,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，东方生物报收于19.2元，较前一交易日下跌2.74%，最新总市值为38.71亿元。该股当日开盘19.53元，最高19.57元，最低19.08元，成交额达2830.84万元，换手率为0.73%。公告显示，浙江东方基因生物制品股份有限公司将于2026年9月10日11:00-12:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司上半年经营成果及财务状况。投资者可于2026年9月3日至9月9日16:00前通过上证路演中心网站或公司邮箱zqb@orientgene.com提交问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100030260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663704582","title":"每周股票复盘：东方生物（688298）股东户数下降6.35%，中报净利亏损2.22亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2663704582","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663704582?lang=zh_cn&edition=full","pubTime":"2026-08-30 09:07","pubTimestamp":1788052029,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，东方生物报收于19.74元，较上周的19.43元上涨1.6%。本周，东方生物8月26日盘中最高价报19.85元。公司对2026年度“提质增效重回报”行动方案上半年执行情况进行评估，报告期内取得177项产品注册证，营业收入同比增长15.15%，但归母净利润同比下降。公司披露2026年半年度募集资金存放、管理与实际使用情况，首次公开发行募集资金净额55,081.78万元，截至2026年6月30日累计使用50,178.43万元，报告期使用金额为0元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663463048","title":"东方生物（688298）2026年中报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663463048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663463048?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:16","pubTimestamp":1788041794,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期东方生物发布2026年中报。截至本报告期末，公司营业总收入4.64亿元，同比上升15.15%，归母净利润-2.22亿元，同比下降36.26%。本报告期东方生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达30.51%。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司现金流状况建议关注财务费用状况本文数据来源于东方生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662009141","title":"东方生物(688298.SH)发布半年度业绩，归母净亏损2.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662009141","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662009141?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:48","pubTimestamp":1787928486,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东方生物 披露2026年半年度报告，报告期公司实现营业收入4.64亿元，同比增长15.15%;归属于上市公司股东的净利润亏损2.22亿元，同比扩大;扣除非经常性损益后的净利润亏损2.38亿元，同比扩大;基本每股收益-1.16元。报告期，公司营业收入比上年同期增长15.15%，主要原因为：境外市场传染病检测试剂销售收入增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"东方生物(688298.SH)发布半年度业绩，归母净亏损2.22亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662963061","title":"图解东方生物中报：第二季度单季净利润同比下降169.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662963061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662963061?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:17","pubTimestamp":1787912277,"startTime":"0","endTime":"0","summary":"证券之星消息，东方生物2026年中报显示，上半年度公司主营收入4.64亿元，同比上升15.15%；归母净利润-2.22亿元，同比下降36.26%；扣非净利润-2.38亿元，同比下降29.23%；其中2026年第二季度，公司单季度主营收入2.08亿元，同比下降1.53%；单季度归母净利润-1.28亿元，同比下降169.46%；单季度扣非净利润-1.33亿元，同比下降100.19%；负债率15.26%，投资收益1191.38万元，财务费用3401.57万元，毛利率43.62%。财报数据概要请见下图:本文数据来源于东方生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066397","title":"东方生物(688298)6月30日股东户数1.2万户，较上期减少6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066397","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066397?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:41","pubTimestamp":1787910098,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东方生物披露，截至2026年6月30日公司股东户数为1.2万户，较3月31日减少813.0户，减幅为6.35%。在医疗器械行业个股中，东方生物股东户数低于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.12万户。从股价来看，2026年3月31日至2026年6月30日，东方生物区间跌幅为21.67%，在此期间股东户数减少813.0户，减幅为6.35%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800040749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648567398","title":"股市必读：东方生物（688298）6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648567398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648567398?lang=zh_cn&edition=full","pubTime":"2026-07-01 05:10","pubTimestamp":1782853825,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，东方生物报收于17.86元，下跌1.6%，换手率0.78%，成交量1.58万手，成交额2816.28万元。董秘最新回复投资者： 截止到6.29，公司股价跌到只有高点的0.071，打一折都不到，公司放任股价下跌，股价长期低于行业水平，试问公司领导有哪一家同行公司的股价有跌到如此之低？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100006080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647513535","title":"东方生物：公司2025年度暨2026年第一季度业绩说明会已于2026年5月13日召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2647513535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647513535?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:09","pubTimestamp":1782806955,"startTime":"0","endTime":"0","summary":"证券之星消息，东方生物06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，我注意到贵公司2024年未提供业绩说明会视频回放。东方生物回复：尊敬的投资者，公司2025年度暨2026年第一季度业绩说明会已于2026年5月13日召开，公司过往业绩说明会问答情况均可在“上证路演”平台查询，类似2024年年度业绩说明会超过一年无法在线查阅相关互动资料的，您可以发送邮件至证券部邮箱zqb@orientgene.com，我们将通过邮件向您提供业绩说明会问答情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647253554","title":"东方生物：公司已根据实际情况，开展降本增效措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2647253554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647253554?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:06","pubTimestamp":1782806793,"startTime":"0","endTime":"0","summary":"证券之星消息，东方生物(688298)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：截止到6.29，公司股价跌到只有高点的0.071，打一折都不到，公司放任股价下跌，股价长期低于行业水平，试问公司领导有哪一家同行公司的股价有跌到如此之低？公司的营业成本及人员长期高于同行业公司，国内到处建无用的厂房，公司业务变差后为什么不能及时裁员和关掉产能利用率低的工厂？东方生物回复：尊敬的投资者您好，公司已根据实际情况，开展降本增效措施，谢谢您的建议！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646610315","title":"每周股票复盘：东方生物（688298）获多项国际医疗器械认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2646610315","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646610315?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:23","pubTimestamp":1782588190,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，东方生物报收于17.47元，较上周的19.24元下跌9.2%。本周，东方生物6月24日盘中最高价报19.8元。本周关注点公司公告汇总：杭州丹威生物获中国NMPA三类医疗器械注册证。公司公告汇总浙江东方基因生物制品股份有限公司及下属子公司近期取得多项医疗器械注册证。杭州丹威生物获得中国NMPA三类医疗器械注册证，产品为腺病毒、肺炎支原体和人鼻病毒核酸联合检测试剂盒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1574","BK1100","159883","BK0239","688298","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365082","title":"东方生物（688298）披露获得多项医疗器械注册证及认证，6月26日股价下跌4.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646365082?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:47","pubTimestamp":1782485236,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，东方生物报收于17.47元，较前一交易日下跌4.27%，最新总市值为35.22亿元。该股当日开盘18.1元，最高18.39元，最低17.44元，成交额达3137.13万元，换手率为0.88%。近日，东方生物披露《关于自愿披露获得医疗器械注册证的公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","09996","BK0239","BK1574","BK1100","159883","688298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646353595","title":"东方生物跌4.27%创新低 2020年上市募6亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2646353595","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646353595?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:09","pubTimestamp":1782464945,"startTime":"0","endTime":"0","summary":" 东方生物于2020年2月5日在上交所科创板上市，本次发行数量为3,000.00万股，全部为公开发行新股，不进行老股转让，发行价格为21.25元/股，保荐机构为光大证券股份有限公司，保荐代表人为孙蓓、储伟。 东方生物本次发行募集资金总额为63,750.00万元，募集资金净额为55,081.78万元。 东方生物本次发行费用总额为8,668.22万元，其中承销及保荐费用6,060.16万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260626/32291170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK1564","BK0239","BK0012","601788","688298","BK1147","06178","BK0028","BK0188","BK0276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793728350809,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.11},{"period":"3month","weight":-0.0936},{"period":"6month","weight":-0.2855},{"period":"1year","weight":-0.3465},{"period":"ytd","weight":-0.2642}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.0926},{"period":"ytd","weight":-0.0909}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江东方基因生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12968人(较上一季度增加8.09%)","perCapita":"15545股","listingDate":"2020-02-05","address":"浙江省湖州市安吉县递铺街道阳光大道东段3787号","registeredCapital":"20160万元","survey":" 浙江东方基因生物制品股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是体外诊断试剂、配套仪器。","listedPrice":21.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东方生物,688298,东方生物股票,东方生物股票老虎,东方生物股票老虎国际,东方生物行情,东方生物股票行情,东方生物股价,东方生物股市,东方生物股票价格,东方生物股票交易,东方生物股票购买,东方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东方生物(688298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东方生物(688298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}